StreetAlpha.app
Home › Stocks › BLLN

BillionToOne, Inc. (BLLN)

Healthcare
$89.92
▼ −0.31%
LAST CLOSE · NOV 20

BillionToOne sells genetic blood tests for prenatal screening and cancer care to doctors and clinics. It last closed at $89.92 on Nov 20, down 0.31% on the day. The next earnings report for BLLN is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, BLLN reported EPS of $0.32 on revenue of $123.0M, with revenue up 47.2% from a year ago. Over its last 6 reports the stock moved an average of 14.3% the session after earnings. Over the last 12 months BLLN insiders bought $0 of stock on the open market and sold $58.5M, according to SEC Form 4 filings.

AI Auto Pilots
Is BLLN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold BLLN.

Key Stats

Last 12 months
Results
Revenue
$436.9M
+71.9% vs a year ago
Net income
$49.4M
11.3% margin
EPS (diluted)
$0.92
Free cash flow
$33.9M
7.8% margin
Balance sheet
Cash & equivalents
$561.5M
At Sep 30
Debt
$89.0M
At Sep 30
Shareholder equity
$566.5M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $71.7M$71.7MFY2023FY2024: $152.6M$152.6MFY2024FY2025: $305.1M$305.1MFY2025

From BLLN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
$0.32
Quarter ended Sep 2026
Year ago EPS
$0.10
+220.0% on a GAAP basis
Revenue
$123.0M
+47.2% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.13Dec '24Mar 2025: -$0.39Mar '25Jun 2025: -$0.02Jun '25Sep 2025: $0.10Sep '25Dec 2025: $0.11Dec '25Mar 2026: $0.34Mar '26Jun 2026: $0.15Jun '26Sep 2026: $0.32Sep '26Latest $0.32
Revenue by quarter
Dec 2024: $45.1MDec '24Mar 2025: $59.0MMar '25Jun 2025: $66.6MJun '25Sep 2025: $83.5MSep '25Dec 2025: $96.1MDec '25Mar 2026: $108.4MMar '26Jun 2026: $109.4MJun '26Sep 2026: $123.0MSep '26Latest $123.0M
How BLLN moved after its last 6 reports
Average move the session after a report ±14.3%
Nov 4, 2026After the close−1.3%
Aug 5, 2026After the close−38.9%
May 6, 2026After the close+14.1%
Mar 4, 2026After the close−10.7%
Jan 12, 2026Time not announced+15.4%
Dec 9, 2025After the close−5.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on BLLNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on BLLN
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on BLLN

Technical Analysis

BLLN · as of the Nov 20 close · updated each morning
Turning down, nearing oversold

The stock is 19% below its 20 day and 18% below its 50 day average. It is 9% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 30), near oversold. The nearest support is the Pivot at $89.78, and the nearest resistance the Pivot R1 at $91.57.

Short trendBearish
Long trendNeutral
MomentumWeak
StretchNear oversold
VolatilityNormal, 7.3%/day
Key levels
$150.4452 week high+67.3%
$109.23100 day average+21.5%
$107.3720 day average+19.4%
$106.4050 day average+18.3%
$100.00Swing high (May 29)+11.2%
$97.90200 day average+8.9%
$91.57Pivot R1+1.8%
$89.92Last close
$89.78Pivot−0.2%
$89.78Swing low (Aug 31)−0.2%
$88.14Pivot S1−2.0%
$61.9652 week low−31.1%
Indicators
RSI (14)30.06Weak, oversold below 30Neutral
MACD-3.65Below its signal lineBearish
Stochastic15.1Near the bottom of its rangeOversold
ADX (14)22.6Weak trend
Williams %R-86.9Oversold below −80, overbought above −20Oversold
CCI (20)-170.3Oversold below −100, overbought above 100Oversold
Rate of change−21.1%Change over 10 sessionsBearish
ATR (14)$6.60Typical daily range, 7.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BLLN

What happened before

See how BLLN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for BLLNHow many large options trades hit BLLN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

BLLN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲118 buying vs 68 selling
  • ▲Shares held by funds +21.3%
  • ▲Funds holding +16
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding172156+10.3%
In funds' top 1047−42.9%
Held by funds–––
New / increased48 / 7077 / 49−6.3%
Reduced / sold out36 / 3213 / 11+183.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BLLN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

BLLN Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$58.5M38 sales · 6 insiders
100% of the selling was under pre-arranged trading plans.
2026-06 sold $9.4M2026-07 sold $12.8M2026-08 sold $10.7M2026-09 sold $13.1M2026-10 sold $6.7M2026-11 sold $5.8MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 2Bosch John Roderick tenSVP of Laboratory OperationsSale plan2,834$113.17$321K
Nov 2David TsaoChief Technology OfficerSale plan20,000$109.24$2.2M
Nov 2Oguzhan AtayChairman and CEOSale plan30,335$109.93$3.3M
Oct 28Oguzhan AtayChairman and CEOSale plan11,000$118.00$1.3M
Oct 15Oguzhan AtayChairman and CEOSale plan11,000$99.14$1.1M
Oct 12Oguzhan AtayChairman and CEOSale plan19,334$94.31$1.8M
Every insider buy and sale for BLLN over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See BLLN insider trades →

From SEC Form 4 filings by BLLN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BLLN is in one of them and how their past BLLN trades turned out.

BLLN in the AI portfolios
Loading…

BLLN News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BLLN in an article yet. Here's the latest on the wider market.

BLLN in the news

About BillionToOne

BillionToOne is a molecular diagnostics company based in Menlo Park, California. It offers genetic tests that analyze cell free DNA from a blood sample, using a sequencing method that counts individual DNA molecules. Its prenatal test, UNITY, assesses fetal genetic risk from a single maternal blood draw. Its Northstar tests are cancer tests used by oncology providers to help select treatments and track how patients respond to therapy.

Headquarters
Menlo Park, CA